An open-label phase II study to assess the immunogenicity and safety of a booster vaccination with a heterologous Vero cell-derived whole virus H5N1 influenza vaccine in a healthy young adult population (follow up to study 810501)

Trial Profile

An open-label phase II study to assess the immunogenicity and safety of a booster vaccination with a heterologous Vero cell-derived whole virus H5N1 influenza vaccine in a healthy young adult population (follow up to study 810501)

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Oct 2015

At a glance

  • Drugs Influenza A vaccine H5N1-Baxter (Primary)
  • Indications Influenza A virus H5N1 subtype
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Baxter Healthcare Corporation
  • Most Recent Events

    • 04 Dec 2008 Actual end date (Oct 2008) added as reported by Clinicaltrials.gov.
    • 04 Dec 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 14 Feb 2008 The expected completion date for this trial is now 1 May 2008 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top